Skip to main content

Huaqing Zhimei

MaterialsShenzhen, Guangdong, ChinaFounded 2021· One of 971 Materials companies tracked by AMPulse

A high-tech biotechnology firm specializing in the industrialization of Bio-3D printing, regenerative synthetic biology, and microfluidic technologies for human-engineered extracellular matrix (hEECM) materials in regenerative medicine and medical aesthetics.

CEO / Founder
Liu Boxun (刘博勋)
Team Size
51-200
Stage
Active
Total Funding
$10.3M
Latest Round
Series A
Key Investors
Leaguer Capital (力合创投), Shaanxi Financial Holding (陕西金控), Zijing Hongxin (紫荆泓鑫)

Technology & Products

Key Products

["h-EECM (Human Engineered Extracellular Matrix) Raw Materials","Meibiyuan (美泌源) Brand - High-end medical aesthetics line","Qingfu Mima (清肤泌码) - Skin repair and regeneration product","Shiguang Mima (时光泌码) - Anti-aging and tissue filling solution","Automated Bio-3D Printing Systems (proprietary R&D equipment)"]

Technological Advantage

Pioneered the transition from 'printing organs' (long-term research) to 'printing factories' (immediate commercialization), solving the scalability and cost issues of high-purity human-derived bioactive materials. Built full-process autonomous equipment system covering cell intelligent printing, AI dynamic culture, and integrated material purification.

Differentiation

Value Proposition

Transforms biological cells into 'super factories' using 3D bioprinting, regenerative synthetic biology, and microfluidic technologies to mass-produce human-derived bioactive materials (hEECM) that offer superior safety and natural tissue regeneration compared to synthetic or animal-derived alternatives.

How They Differentiate

Huaqing Zhimei differentiates through its 'Super Cell Factory' model. Unlike competitors who focus on recombinant single-protein collagen (expressed in yeast/E.coli), Huaqing Zhimei uses proprietary Bio-3D printing to create structured environments where human cells secrete a complete 'Human Engineered Extracellular Matrix' (hEECM) containing over 1,000 types of active proteins, achieving 100% bio-homology.

Market & Competition

Target Customers

Medical aesthetics clinics, dermatology hospitals, plastic surgery centers, and pharmaceutical research institutions.

Industry Verticals

["Medical Aesthetics","Regenerative Medicine","Tissue Engineering","Biotechnology"]

Competitors

Giant Biogene (巨子生物); Bloomage Biotech (华熙生物); Trautec (创健医疗); Regenovo (捷诺飞)

Growth & Milestones

Growth Metrics

Operating GMP workshop with universal 10,000-level and local 100-level clean rooms in Shenzhen; established the first national industry standard for Extracellular Matrix (ECM) in China; built international first large-scale 3D printed cell-level material production line.

Major Milestones

["Established the first national industry standard for ECM in China (2023)","Successful launch of the 'Meibiyuan' (美泌源) high-end regenerative aesthetics brand","Completion of GMP bioactive material production line in Shenzhen with 10,000-level clean rooms (2024)","Series A funding round of tens of millions of CNY (June 2024)","Completed Series A funding extension of ¥30.0M (~$4.1M) led by Leaguer Capital (January 2026)","Built international first large-scale 3D printed cell-level material production line (2025-2026)"]

Notable Customers

Class-A Hospitals in China; High-end Medical Aesthetics Clinics; Dermatology Research Institutions

Recent coverage of Huaqing Zhimei

Why this company matters

Huaqing Zhimei occupies a distinctive position at the intersection of bioprinting and regenerative medicine, commercializing human-engineered extracellular matrix (hEECM) materials as an alternative to synthetic fillers or animal-derived collagen. The company's core innovation is its 'Super Cell Factory' model, which uses material extrusion (MEX) bioprinting to create structured microenvironments where human cells secrete a complete ECM with over 1,000 types of active proteins, achieving 100% bio-homology. This approach shifts the industry focus from printing organs to printing factories for immediate commercial production of bioactive materials.

The company's product portfolio spans raw hEECM materials and branded medical aesthetics lines including Meibiyuan for regenerative aesthetics, Qingfu Mima for skin repair, and Shiguang Mima for anti-aging and tissue filling. These products target high-end medical aesthetics clinics, dermatology hospitals, and plastic surgery centers in China. Huaqing Zhimei also develops proprietary automated bioprinting systems for in-house production. The company operates a 2,000-square-meter GMP-standard facility in Shenzhen and, in 2023, helped establish China's first national industry standard for extracellular matrix materials.

Huaqing Zhimei differentiates from competitors such as Giant Biogene and Bloomage Biotech, which focus on recombinant single-protein collagen expressed in yeast or E. coli. By delivering a complete human-derived ECM with native protein diversity, the company claims superior safety and natural tissue regeneration. The company was incubated at the Research Institute of Tsinghua University in Shenzhen and raised $10.3 million from investors including Leaguer Capital, Shaanxi Financial Holding, and Zijing Hongxin. A key open question is whether the Super Cell Factory model can scale cost-effectively to compete with established recombinant collagen producers in the high-volume aesthetics market.